PubRank

The Biologic Onset of Crohn's Disease: A Screening Study in First Degree Relatives

Clinical Trial ID NCT03291743

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT03291743

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979 71.07
2 Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008 10.47
3 The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 2014 7.43
4 Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2006 6.88
5 Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011 6.43
6 Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science 2012 5.34
7 A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with non-stricturing small bowel Crohn's disease. Am J Gastroenterol 2006 4.86
8 Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001 4.23
9 Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002 4.13
10 Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998 4.08
11 Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011 3.52
12 Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 2011 3.36
13 Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2006 3.32
14 Regulatory T cells reinforce intestinal homeostasis. Immunity 2009 3.27
15 Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. Clin Gastroenterol Hepatol 2010 2.79
16 The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 2014 2.73
17 Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms. Gut 1988 2.51
18 Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007 2.34
19 A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005 2.17
20 A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002 2.15
21 Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol 2013 2.05
22 Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005 2.05
23 Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am J Gastroenterol 1998 2.03
24 Subclinical intestinal inflammation: an inherited abnormality in Crohn's disease relatives? Gastroenterology 2003 2.03
25 Different intestinal permeability patterns in relatives and spouses of patients with Crohn's disease: an inherited defect in mucosal defence? Gut 1999 2.01
26 Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. Gastroenterology 2008 1.88
27 Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology 1997 1.84
28 Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol 2010 1.82
29 Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008 1.78
30 Development of a capsule endoscopy scoring index for small bowel mucosal inflammatory change. Aliment Pharmacol Ther 2007 1.75
31 Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 2005 1.73
32 Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 2008 1.72
33 From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology 2004 1.68
34 Epidemiological study of asymptomatic inflammatory bowel disease: the identification of cases during a screening programme for colorectal cancer. Gut 1989 1.65
35 Serological markers predict inflammatory bowel disease years before the diagnosis. Gut 2012 1.64
36 Prediction of the need for surgical intervention in obstructive Crohn's disease by 18F-FDG PET/CT. J Nucl Med 2009 1.54
37 Colonic mucosal abnormalities associated with oral sodium phosphate solution. Gastrointest Endosc 1996 1.53
38 Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn's disease: partial benefit by infliximab--a pilot study. Dig Dis Sci 2012 1.50
39 Pathogenesis of aphthoid ulcers in Crohn's disease: correlative findings by magnifying colonoscopy, electron microscopy, and immunohistochemistry. Gut 1996 1.48
40 Diagnostic accuracy of capsule endoscopy for small bowel Crohn's disease is superior to that of MR enterography or CT enterography. Clin Gastroenterol Hepatol 2010 1.47
41 Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis 2011 1.41
42 Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004 1.36
43 Reconsidering the criteria for evaluating proposed screening programs: reflections from 4 current and former members of the U.S. Preventive services task force. Epidemiol Rev 2011 1.33
44 American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology 2013 1.32
45 Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflamm Bowel Dis 2014 1.29
46 Peyer's patches and M cells as potential sites of the inflammatory onset in Crohn's disease. Ann N Y Acad Sci 2006 1.28
47 Frequency of inflammatory bowel disease in offspring of couples both presenting with inflammatory bowel disease. Gastroenterology 1991 1.27
48 Review article: the genetics of inflammatory bowel disease. Aliment Pharmacol Ther 2001 1.25
49 NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology 2006 1.20
50 Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis. Gastroenterology 2010 1.20
51 Familial expression of anti-Saccharomyces cerevisiae Mannan antibodies in Crohn's disease and ulcerative colitis: a GISC study. Am J Gastroenterol 2001 1.17
52 Mycobiota in gastrointestinal diseases. Nat Rev Gastroenterol Hepatol 2014 1.10
53 Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease. Gastroenterology 2006 1.08
54 Candida albicans colonization and ASCA in familial Crohn's disease. Am J Gastroenterol 2009 1.07
55 Family studies in Crohn's disease: new horizons in understanding disease pathogenesis, risk and prevention. Gut 2011 1.05
56 Intestinal permeability and genetic determinants in patients, first-degree relatives, and controls in a high-incidence area of Crohn's disease in Southern Italy. Am J Gastroenterol 2005 1.00
57 The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis--how much is irritable bowel syndrome? Clin Gastroenterol Hepatol 2006 1.00
58 Risk of ulcerative colitis and Crohn's disease among offspring of patients with chronic inflammatory bowel disease. Am J Gastroenterol 1999 0.97
59 Subclinical intestinal inflammation and sacroiliac changes in relatives of patients with ankylosing spondylitis. Gastroenterology 2003 0.97
60 Goblet cell autoantibodies in patients with inflammatory bowel disease and their first-degree relatives. Gastroenterology 1997 0.95
61 Epidemiology and clinical course of Crohn's disease: results from observational studies. World J Gastroenterol 2012 0.95
62 Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn's disease and their unaffected siblings. Gut 2014 0.94
63 Genetic studies of Crohn's disease: past, present and future. Best Pract Res Clin Gastroenterol 2014 0.94
64 Distinct profiles of effector cytokines mark the different phases of Crohn's disease. PLoS One 2013 0.94
65 Management of active Crohn disease. JAMA 2013 0.93
66 The early histological lesion of Crohn's disease. Proc R Soc Med 1972 0.93
67 Environmental risk factors for inflammatory bowel diseases: a review. Dig Dis Sci 2014 0.92
68 Delayed diagnosis is influenced by the clinical pattern of Crohn's disease and affects treatment outcomes and quality of life in the long term: a cross-sectional study of 361 patients in Southern Italy. Eur J Gastroenterol Hepatol 2015 0.91
69 The chronological sequence in the pathology of Crohn's disease. J Clin Gastroenterol 1988 0.91
70 Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy. Scand J Gastroenterol 2012 0.90
71 Catching the therapeutic window of opportunity in early Crohn's disease. Curr Drug Targets 2014 0.89
72 Capsule endoscopy is superior to small-bowel follow-through and equivalent to ileocolonoscopy in suspected Crohn's disease. Clin Gastroenterol Hepatol 2013 0.89
73 Diagnostic delay in Crohn's disease is associated with increased rate of abdominal surgery: A retrospective study in Chinese patients. Dig Liver Dis 2015 0.87
74 Familial occurrence of complement dysfunction in Crohn's disease: correlation with intestinal symptoms and hypercatabolism of complement. Gut 1985 0.86
75 Fecal calprotectin in first-degree relatives of patients with ulcerative colitis. Am J Gastroenterol 2006 0.85
76 The mycobiome: influencing IBD severity. Cell Host Microbe 2012 0.83
77 Subclinical inflammation with increased neutrophil activity in healthy twin siblings reflect environmental influence in the pathogenesis of inflammatory bowel disease. Inflamm Bowel Dis 2013 0.83
78 Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy. Scand J Gastroenterol 2010 0.83
79 Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data. Inflamm Bowel Dis 2012 0.82
80 Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis. Pharmacoepidemiol Drug Saf 2011 0.82
81 Role of biologics and other therapies in stricturing Crohn's disease: what have we learnt so far? Digestion 2008 0.81
82 The complexity and challenges of genetic counseling and testing for inflammatory bowel disease. J Genet Couns 2006 0.81
83 Serological studies in inflammatory bowel disease: how important are they? Curr Opin Gastroenterol 2014 0.81
84 Characterization of lymphoid follicles with red ring signs as first manifestation of early Crohn's disease by conventional histopathology and confocal laser endomicroscopy. Int J Clin Exp Pathol 2012 0.81
85 Clinical characteristics of familial versus sporadic Crohn's disease using the Vienna Classification. Inflamm Bowel Dis 2004 0.81
86 Fecal calprotectin in Crohn's disease: new family ties. Gastroenterology 2003 0.80
87 The strategy for biopsies of the terminal ileum should be evidence based. Am J Gastroenterol 2007 0.79
88 What is the risk that a child will develop inflammatory bowel disease if 1 or both parents have IBD? Inflamm Bowel Dis 2008 0.78
89 Antinuclear autoantibodies in patients with inflammatory bowel disease. High prevalence in first-degree relatives. Dig Dis Sci 1997 0.78
90 Step-up and top-down approaches to the treatment of Crohn's disease: early may already be too late. Gastroenterology 2008 0.77
91 A family study of asymptomatic small bowel Crohn's disease. Dig Liver Dis 2013 0.77
92 Diagnosis and assessment of Crohn's disease: the present and the future. Expert Rev Gastroenterol Hepatol 2010 0.77
93 Editorial: Can stenosis in ileal Crohn's disease be prevented by current therapy? Am J Gastroenterol 2013 0.76
94 Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn's Disease. J Crohns Colitis 2015 0.76
95 Course of Crohn's disease prior to establishment of the diagnosis. Z Gastroenterol 2008 0.75
96 I am Jewish: what is my risk of developing Crohn's disease? Inflamm Bowel Dis 2008 0.75
97 Preclinical and Undiagnosed Crohn's Disease: The Submerged Iceberg. Inflamm Bowel Dis 2016 0.75
98 A subgroup of first-degree relatives of Crohn's disease patients shows a profile of inflammatory markers in the blood which is more typical of Crohn's disease patients than of normal individuals. Mediators Inflamm 2006 0.75
99 Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2016 0.75
100 Surgery for Crohn's disease and anti-TNF agents: the changing scenario. Expert Rev Gastroenterol Hepatol 2013 0.75
Next 100